Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7+3 Type Chemotherapy or Venetoclax/Azacitidine

被引：5

作者：

Islam, Nazmul ^{[1
]}

Reuben, Jamie S. ^{[2
]}

Dale, Justin ^{[3
]}

Gutman, Jon ^{[3
]}

McMahon, Christine M. ^{[3
]}

Amaya, Maria ^{[3
]}

Goodman, Bruce ^{[1
]}

Toninato, Joseph ^{[1
]}

Gasparetto, Maura ^{[3
]}

Stevens, Brett ^{[3
]}

Pei, Shanshan ^{[3
]}

Gillen, Austin ^{[3
]}

Staggs, Sarah ^{[3
]}

Engel, Krysta ^{[3
]}

Davis, Sarah ^{[3
]}

Hull, Madelyne ^{[4
]}

Burke, Elizabeth ^{[2
]}

Larchick, Lenny ^{[2
]}

Zane, Richard ^{[5
,6
]}

Weller, Grant ^{[1
]}

Jordan, Craig ^{[3
]}

Smith, Clay ^{[3
]}

机构：

[1] Optum Labs, Minnetonka, MN USA

[2] UCHealth, Aurora, CO USA

[3] Univ Colorado, Dept Med, Aurora, CO USA

[4] Univ Colorado, Colorado Ctr Personalized Med, Hlth Data Compass, Aurora, CO USA

[5] Univ Colorado, UCHlth Care Innovat, Aurora, CO USA

[6] Univ Colorado, Dept Emergency Med, Aurora, CO USA

来源：

JCO CLINICAL CANCER INFORMATICS | 2022年 / 6卷

关键词：

TARGETED THERAPIES; REGRESSION-MODELS; VENETOCLAX; MANAGEMENT; AZACITIDINE; AML;

D O I：

10.1200/CCI.22.00030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThere are currently limited objective criteria to help assist physicians in determining whether an individual patient with acute myeloid leukemia (AML) is likely to do better with induction with either standard 7 + 3 chemotherapy or targeted therapy with venetoclax plus azacitidine. The study goal was to address this need by developing exploratory clinical decision support methods.PATIENTS AND METHODSUnivariable and multivariable analysis as well as comparison of a range of machine learning (ML) predictors were performed using cohorts of 120 newly diagnosed 7 + 3-treated AML patients compared with 101 venetoclax plus azacitidine-treated patients.RESULTSA variety of features in the two patient cohorts were identified that may potentially correlate with short- and long-term outcomes, toxicities, and other considerations. A subset of these diagnostic features was then used to develop ML-based predictors with relatively high areas under the curve of short- and long-term outcomes, hospital stays, transfusion requirements, and toxicities for individual patients treated with either venetoclax/azacitidine or 7 + 3.CONCLUSIONPotential ML-based approaches to clinical decision support to help guide individual patients with newly diagnosed AML to either 7 + 3 or venetoclax plus azacitidine induction therapy were identified. Larger cohorts with separate test and validation studies are necessary to confirm these initial findings.

引用

页数：13

共 64 条

[1] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia [J].